Literature DB >> 26179521

Pathogenesis of Cholangiolocellular Carcinoma: Possibility of an Interlobular Duct Origin.

Fukuo Kondo1, Toshio Fukusato.   

Abstract

Cholangiolocellular carcinoma (CoCC) is categorized as a different entity from ordinary intrahepatic cholangiocarcinoma (ICC) due to its unique clinical, radiological and histological features. The lesion is supposed to originate from cholangioles, where hepatic stem/progenitor cells exist. However, the interlobular duct is also speculated to be the origin of CoCC. According to the findings of morphometric and immunohistochemical studies, CoCC closely resembles the interlobular duct. The unique clinical and pathological features of this disease can also be explained by the interlobular duct origin theory. The malignant counterparts of cholangioles and interlobular ducts have been categorized as CoCC to date. In order to differentiate between true CoCC (cholangiole origin) and pseudo-CoCC (interlobular duct origin), assessing the size of the cancer duct, positivity for c-Kit and coexistence of an ordinary ICC component is useful.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26179521     DOI: 10.2169/internalmedicine.54.3540

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

2.  S-1 monotherapy in a patient with cholangiolocellular carcinoma: A case report.

Authors:  Takashi Yamaguchi; Toshihito Seki; Ryosuke Inokuchi; Rinako Kawamura; Miki Murata; Koichi Matsuzaki; Osamu Nakashima; Tsutomu Kumabe; Kazuichi Okazaki
Journal:  Mol Clin Oncol       Date:  2016-10-11

3.  Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.

Authors:  Yusuke Ono; Yutaro Hiratsuka; Masaki Murata; Akira Takasawa; Rieko Fukuda; Masanori Nojima; Satoshi Tanaka; Makoto Osanai; Koichi Hirata; Norimasa Sawada
Journal:  Virchows Arch       Date:  2016-07-21       Impact factor: 4.064

4.  Small cholangiolocellular carcinoma that was difficult to distinguish from cholangiocellular carcinoma: a case report.

Authors:  Norihiro Ishii; Kenichiro Araki; Takahiro Yamanaka; Tadashi Handa; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Norio Kubo; Shinichi Aishima; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Case Rep       Date:  2017-09-15

5.  Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection.

Authors:  Mitsutaka Osawa; Satoshi Saitoh; Shunichiro Fujiyama; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Fumitaka Suzuki; Kenji Ikeda; Keiichi Kinowaki; Takeshi Fujii; Toshio Fukusato; Fukuo Kondo; Hiromitsu Kumada
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

6.  Successfully Treated Case of Cholangiolocellular Carcinoma with a Poor Hepatic Functional Reserve Reporting with Various Imaging Findings.

Authors:  Satoshi Takakusagi; Yozo Yokoyama; Kazuko Kizawa; Kyoko Marubashi; Takashi Kosone; Ken Sato; Satoru Kakizaki; Kenichi Harada; Hitoshi Takagi; Toshio Uraoka
Journal:  Intern Med       Date:  2020-10-14       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.